# Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification

> **NCT07687004** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 50 (estimated)

## Conditions studied

- Multiple Myeloma (MM)

## Interventions

- **DRUG:** Sonrotoclax
- **DRUG:** CM336 (BCMA/CD3 bispecific antibody)

## Key facts

- **NCT ID:** NCT07687004
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2027-08-01
- **Final completion:** 2029-08-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07687004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07687004, "Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07687004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*